Tag Archives: NIH

New Small Business Grant from NIH Heart, Lung and Blood Institute

Phoenicia scientists were recently awarded a Phase 2 Small Business Grant from the NIH NHLBI (“Development of a Clinical Hemoglobin Modulator” R42 HL-110727-02) to support clinical development of PB-04, the lead drug candidate for the treatment of β-thalassemia and sickle cell disease

Phoenicia’s Lead Drug for Hemoglobinopathies selected by NIH-TRND Program

image1445 Phoenicia’s lead drug candidate for the treatment of β-thalassemia and sickle cell disease (PB-04), was recently selected as a project within the Therapeutics for Rare and Neglected Diseases program at the NIH’s National Center for Advancing Translational Sciences. Through our collaboration with TRND researchers, we gain access to preclinical drug development expertise. The goal of the TRND program is to work with collaborators to advance potential treatments to human clinical trials.